This article is more than 5 years old. Information may no longer be current.
AI could eliminate biopsies, change diagnosis of thyroid nodules — top stories in endocrinology
The top stories in endocrinology last week focused on how artificial intelligence, or AI, could be a game-changer in predicting nonalcoholic fatty liver disease and detecting thyroid nodules.
Learn more here.
AI tool for nonalcoholic fatty liver disease could ‘make biopsies history’
In this video from the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, discusses a new AI and machine learning tool for nonalcoholic fatty liver disease prediction. Watch video.
Future of thyroid nodule classification driven by AI , machine learning as support tools
The detection and diagnosis of thyroid nodules may be on the cusp of a technological overhaul as a growing body of research on AI and machine learning tools aims to bring about more efficiency and accuracy while decreasing cost and improving ease-of-use. Read more.
FDA committee unanimously recommends approval of teprotumumab for thyroid eye disease
The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted 12-0 last week in favor of recommending approval of a biologics license application for teprotumumab, an experimental human monoclonal antibody shown to dramatically reduce the most debilitating symptoms of Graves’ orbitopathy. Read more.
Associations urge caution after controversial radioactive iodine findings
The Society for Endocrinology and the British Thyroid Association issued a joint statement urging caution when interpreting a recent study linking radioactive iodine therapy to cancer mortality among people with hyperthyroidism. Read more.
Low-dose aspirin fails to lower dementia risk among all adults with type 2 diabetes, but may benefit women
Japanese adults with type 2 diabetes assigned a long-term low-dose aspirin regimen did not lower their risk for dementia vs. similar adults who did not routinely take aspirin, according to a post hoc analysis of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial. Read more.